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logical studies (5) have eliminated chronic acalculous 
cholecystitis as a pathological entity characterized by 
chronic inflammation and fibrous and muscular 
thickness of the gallbladder wall. 
Undoubtedly, chronic right upper quadrant pain in 
the absence of gallstone disease is multifactorial. Sludge 
and gallstones must be eliminated by ultrasonography; 
abnormal bile should be sought by examining the 
duodenal aspirate for the presence of cholesterol 
crystals. Overt causes of impairing gallbladder motor 
function (e.g., progesterone, obesity and diabetes) must 
be eliminated (10). Only then will impaired gallbladder 
evacuation be properly related to  symptoms and 
outcome. 
In the interim the ejection fraction ascertained by 
quantitative cholescintigraphy is a reasonable tool for 
identifying disordered gallbladder motility and relating 
this to  biliary symptoms. Even pain relief soon after 
surgery is an imperfect endpoint because of placebo 
effect. The advent of laparoscopic cholecystectomy will 
be a temptingly easy solution to difficult cases. Before 
becoming too haphazard, a more complete, careful 
evaluation of gallbladder function and contents is 
essential. The once elusive testb) to diagnose acalculous 
biliary pain are being clarified. Cholescintigraphy may 
yet provide the best bet. 
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GENETIC STRUCTURE AND HETEROGENEITY OF 
HEPATITIS C VIRUS: A VACCINE IMPEDIMENT? 
Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong 
C, Gallegos C, et al. Genetic organization and diversity 
of the hepatitis C virus. Proc Natl Acad Sci USA 
1991;88:2451-55. 
ABSTRACT 
The nucleotide sequence of the RNA genome of the 
human hepatitis C virus (HCV) has been determined 
from overlapping cDNA clones. The sequence (9379 
nucleotides) has a single large open reading frame that 
could encode a viral polyprotein precursor of 3011 
amino acids. While there is little overall amino acid and 
nucleotide sequence homology with other viruses, the 
5' HCV nucleotide sequence upstream of this large 
open reading frame has substantial similarity to the 5' 
termini of pestiviral genomes. The polyprotein also has 
significant sequence similarity to helicases encoded by 
animal pestiviruses, plant potyviruses, and human 
flaviviruses, and it contains sequence motifs widely 
conserved among viral replicases and trypsin-like pro- 
teases. A basic, presumed nucleocapsid domain is 
located at the N terminus upstream of a region con- 
taining numerous potential N-linked glycosylation 
sites. These HCV domains are located in the same 
relative position as observed in the pestiviruses and 
flaviviruses and the hydrophobic profiles of all three 
viral polyproteins are similar. These combined data 
indicate that HCV is an unusual virus that is most 
related to the pestiviruses. Significant genome di- 
versity is apparent within the putative 5' structural 
gene region of different HCV isolates, suggesting the 
presence of closely related but distinct viral genotypes. 
Kato N,  Hijikata M, Ootsuyarna Y, Nakagawa M ,  
Ohkoshi S, Shimotohno K. Sequence diversity of hepa- 
titis C viral genomes. Mol Biol Med 1990;7:495-501. 
ABSTRACT 
The nucleotide sequences of cDNAs (275 base-pairs) 
in the non-structural protein 5 regions of Japanese 
isolates of hepatitis C virus (HCV-J) from the plasma of 
11 patients with non-A, non-B hepatitis and the livers 
of five patients with hepatocellular carcinoma were 
analyzed. Approximately 14 to 17% of nucleotide se- 
quences of the HCV-Js examined differed from that of 
the original isolate in the United States (HCV-US). 
Furthermore, 2.5 to 11% sequence diversity was found 
among the HCV-Js. The nucleotide sequences of the 
HCV- Js showed characteristic common differences 
from that of HCV-US, although they also showed some 
random substitutions. Plural HCV- J genomes were 
found in two of the cDNAs derived from liver spec- 
imens, and a deletion of 102 nucleotides was found in 
the cDNA derived from one plasma specimen. These 
results suggest that HCV-J is a strain different from the 
HCV-US and that mutation of the viral genome occurs 
at as high a frequency as in that of the human 
immunodeficiency virus. 
COMMENTS 
Recently, several groups reported the initial struc- 
tural details of the hepatitis C viral genome (1, 2). Two 
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FIG. 1. Hepatitis C virus genomic map. The box represents the open 
reading frame that would encode the 3011 amino acid precursor 
protein. Proteolytic cleavages would generate the following putative 
viral proteins: C = RNA-binding nucleocapsid protein; E l  = 
envelope; E2/NS1 = envelope/nonstructural protein 1; NS2-5 = 
nonstructural proteins 2-5. 
such reports are reviewed here along with the current 
knowledge of hepatitis C virus (HCV) genetic heteroge- 
neity. The first paper is from the Chiron group that 
isolated and cloned the HCV in 1988 and reports the 
genomic sequence of the virus. Choo et al. isolated and 
sequenced overlapping complementary DNA (cDNA) 
clones from a cDNA library prepared from infectious 
chimpanzee plasma. The sequence determined was 
9,379 nucleotides long and contained a single large open 
reading frame. This open reading frame could encode a 
polyprotein precursor of 3,011 amino acids that pre- 
sumably is proteolytically cleaved to form the various 
viral proteins. Computer analysis of nucleotide and 
deduced amino acid sequences showed very little se- 
quence homology to other known viruses. Several small 
portions of the genome had sequence similarity to both 
human flaviviruses (e.g., yellow fever virus) and animal 
pestiviruses (e.g., bovine viral diarrhea virus). These 
clues suggested that the overall genomic structure of 
these viruses might be similar, and indeed hydropathy 
plots of the viral polyproteins showed remarkable 
similarity. The presumed genomic structure of hepatitis 
C is shown in Figure 1. Structural proteins are located 
at the 5' end of the genome and appear to encode 
nucleocapsid and envelope proteins. Five nonstructural 
proteins make up the remainder of the polyprotein and 
are currently named NS1 through NS5. NS3 contains 
some structural homology to serine proteases such as 
trypsin and other viral proteases and presumably en- 
codes an enzymatic activity that helps to cleave the large 
viral proprotein (cellular proteases may also be in- 
volved). NS4 contains the antigenic sequence that is 
currently detected by commercial HCV ELISA assays 
((2100). NS5 appears to be the viral RNA-dependent 
RNA polymerase. In addition, the 5' upstream region 
preceding the open reading frame has significant ho- 
mology to animal pestiviruses consistent with this 
region encoding important translational and/or tran- 
scriptional regulatory elements. The overall sequence 
similarities suggest that HCV is most closely related to 
pestiviruses. 
One of the main questions for vaccine development in 
human viral disease is the degree of structural hetero- 
geneity between different viral strains. If such hetero- 
geneity is stable it may be possible to prepare polyvalent 
vaccines such as the trivalent polio vaccine. A more 
ominous heterogeneity is that which is unstable and 
even continually evolving, as may be the case for the 
human immunodeficiency virus (HIV). To begin to  
understand HCV diversity the second paper used poly- 
merase chain reaction amplification and sequencing of a 
275-bp fragment of NS5 (encoding 91 amino acids). 
Sixteen Japanese patients were analyzed and compared 
with the original United States isolate sequenced above. 
The Japanese isolates differed from the original United 
States isolate by 14% to 17% in nucleotide sequence. Of 
greater interest, 7 of 91 amino acids in this putative 
polymerase (NS5) segment were always different as 
compared with the United States isolate and were 
essentially identical among the Japanese patients. Scat- 
tered single amino acid changes were found in individual 
Japanese isolates, but overall their homology was much 
higher in comparison with the United States isolate. 
Although this paper only looked at a very small portion 
of the HCV genome it suggests that different viral 
genotypes exist and raises questions about the effect of 
genetic heterogeneity on vaccine development. 
A thorough review of HCV genetic heterogeneity was 
recently published in this journal (3) and further de- 
velops many of the findings in these papers by comparing 
all published HCV sequences. Analysis of this sequence 
data reveals three groups of HCV genotypes (called HCV 
I, I1 and 111). Multiple genotypes from different HCV 
groups have been found in Japan and Europe, whereas 
only group I HCV viruses have been found in the United 
States. Further sequence data must be obtained from 
HCV isolates to answer several important questions, 
which include the following: Are there other groups of 
HCV genotypes? How rapidly is this virus evolving? Does 
HCV continue to  evolve/mutate in individual patients? 
Can individuals be infected with more than one geno- 
type? The availability of polymerase chain reaction has 
made it possible to analyze these issues with a speed and 
efficiency previously (circa 1985) unimaginable. Ogata et 
al. (4) analyzed HCV isolates obtained from blood col- 
lected in 1977 and 1990 from the same patient (4). The 
two isolates differed at  123 of 4923 nucleotides (2.5%) in 
a patient with no known HCV exposures during this 
13-yr interval. Assuming that the virus continuously 
replicated during this time, the authors calculated a mu- 
tation rate of approximately 10 ~ nucleotide substitu- 
tions per site per year. This mutation rate is similar to  
that of other RNAviruses and about a millionfold higher 
than seen with chromosomal DNA. Viral RNA poly- 
merases lack a proofreading function present in DNA 
polymerases that may explain these markedly different 
mutation rates. The clinical implications of such high 
mutation frequencies are not yet known. 
Mutation of particular viral proteins may have far- 
reaching consequences. The viral envelope protein pro- 
trudes from the virion particle and not only mediates 
important functions such as viral attachment and/or cell 
entry but also provides the antigenic signature that 
identifies specific virions to the immune system. Hyper- 
variable regions within the envelope protein have been 
well defined in the HIV (5-7). These regions may permit 
escape of new viral strains from immune surveillance. 
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An evolving body of information on HCV envelope 
sequences appears to show similar hypervariable re- 
gions. The biological implications of such “new enve- 
lope” viruses were investigated recently (8). Four 
chimpanzees were serially inoculated with different 
infectious strains of HCV. After the first inoculation, 
each animal had acute hepatitis and anti-HCV develop. 
After recovery and infection with a different HCV strain, 
viremia reappeared with infection by the second viral 
strain (confirmed by polymerase chain reaction and 
sequencing). Animals simultaneously had elevations in 
ALT develop, and one had acute hepatitis develop. Two 
animals were challenged four times with the same 
results. The authors concluded that infection of chim- 
panzees with HCV did not provide immunity to heter- 
ologous or homologous HCV. Could this be the experi- 
mental correlate of patients who have multiple episodes 
of NANB hepatitis develop? 
If this family of HCV is continuing to evolve at  a rapid 
rate the production of effective vaccines could be 
compromised. The ability to produce an effective HBV 
vaccine was facilitated by the biology of HBV. HBV uses 
a different polymerase for replication that may well have 
a lower mutation frequency. In addition, the HBV 
genome has severe size constraints with overlapping 
genes that may not allow replication of viral mutants. 
HCV may present a vaccine challenge more similar to 
HIVs than its hepatotropic relatives. 
DARYL DAUGHERTY 
University of Michigan 
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